Breaking News

CordenPharma Colorado Attains SafeBridge Certification

By Kristin Brooks | January 27, 2014

Demonstrates proficiency in the safe handling of potent APIs and compounds

CordenPharma Colorado (CPC), an API manufacturing facility in Boulder, CO, has received approval for the "Potent Compound Safety Certification" by SafeBridge Consultants, Inc. The SafeBridge program has certified CordenPharma Colorado as competent and proficient in the safe handling of potent APIs and compounds of unknown toxicity and potency. The certification applies to specific lab and manufacturing areas involved in the manufacture of APIs and synthetic intermediates.
SafeBridge conducted a 60-element review of health and safety programs, procedures, exposure controls, and process containment of synthetic chemistry operations with occupationally potent APIs at the company's site. The Potent Compound Safety Certification program evaluates performance with established criteria in management, compound evaluation, exposure control, and communication elements of production operations. Elements of the program include on-site assessment of the potent compound manufacturing and lab areas and equipment, training, toxicology as well as industrial hygiene.
The CordenPharma Colorado API facility is now one of 12 facilities worldwide that are certified in the SafeBridge Potent Compound Safety program.

Related Contract Manufacturing:

Related Compliance:

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain